Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2008

View Archived Issues

Benzofuran analogues inhibit amyloid-beta aggregation

Preclinical studies demonstrate PSN-119-2's potential as an antidiabetic with anorectic effects

First-in-man study supports bevacizumab-eluting stent development

Alexza's Staccato loxapine phase III trial in schizophrenic patients meets primary endpoint

SAR-114646 prevents ventricular fibrillation without prolonging ventricular repolarization in dogs

YSPSL safe in phase I/II study in renal transplant patients

Duloxetine shows promise in premenstrual dysphoric disorder in preliminary study / News in Context

Pharmaleads reports on dual NEL/APN inhibitor for pain

Integral Molecular initiates NIAID sponsored R&D program in influenza inhibitors

New treatment options for neurological disorders disclosed in recent patents

Pfizer and Medivation sign global agreement to codevelop and market Dimebon

Neurologix licenses XIAP gene for treatment of HD from Aegera

Opexa and MRF sign research collaboration in MS to support development of Tovaxin

Optimer completes enrollment in second phase III prulifloxacin trial

Acucela and Otsuka enter agreement for ACU-4429 in dry AMD

FDA grants fast track designation to Neurotech's NT-501 for retinitis pigmentosa and dry AMD

Pharmaxis enrolls patients in second pivotal phase III cystic fibrosis trial

Ablynx and Merck Serono to codiscover and codevelop Nanobodies

Antisoma commences phase II trial of AS-1411 in renal cell carcinoma

Recent patents describe new antidiabetic agents

Cytotopia starts enrollment in phase II CYT-997 study in glioblastoma multiforme

Novel therapeutic agents for obesity reported in recent Taisho patent

ImClone submits sBLA for Erbitux in first-line head and neck cancer

Phase III aclidinium studies show statistical significance in patients with COPD

Teva and Barr receive FTC request for additional acquisition information

Zentiva's Board continues to advise shareholders to reject sanofi takeover offer

Celator receives FDA orphan drug designation for anticancer agent CPX-351

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...